HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of zuclopenthixol on aggressive disruptive behavior in adults with mental retardation--a 2-year follow-up on a withdrawal study.

AbstractINTRODUCTION:
People with mental retardation often display aggressive behavior against themselves or others making care within institutions or foster families difficult. Due to a lack of viable alternatives, antipsychotics of the first and second generations are often used for long-term treatment despite the fact that only data about short-term treatment exist.
METHODS:
A short-time withdrawal trial of 12 weeks (n = 39) was extended at open label to 2 years. 31 patients received zuclopenthixol after the end of the withdrawal and were examined using the same instruments as in the withdrawal period (DAS, MOAS, CGI).
RESULTS:
Patients still treated with zuclopenthixol after 2 years (n = 21) benefitted, compared to the drop-outs (n = 10). Analyses of time trends revealed an early effect of zuclopenthixol which could not be enhanced afterwards.
DISCUSSION:
Zuclopenthixol proved to be safe and effective to keep a lower rate of aggressive behavior in adults with mental retardation also over a longer period of time.
AuthorsF Hässler, T Glaser, O Reis
JournalPharmacopsychiatry (Pharmacopsychiatry) Vol. 44 Issue 7 Pg. 339-43 (Nov 2011) ISSN: 1439-0795 [Electronic] Germany
PMID21993867 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© Georg Thieme Verlag KG Stuttgart · New York.
Chemical References
  • Antipsychotic Agents
  • Clopenthixol
Topics
  • Adult
  • Aggression (psychology)
  • Antipsychotic Agents (adverse effects, therapeutic use)
  • Attention Deficit and Disruptive Behavior Disorders (drug therapy, psychology)
  • Clopenthixol (administration & dosage, adverse effects, therapeutic use)
  • Double-Blind Method
  • Endpoint Determination
  • Female
  • Follow-Up Studies
  • Humans
  • Intellectual Disability (psychology)
  • Male
  • Middle Aged
  • Prospective Studies
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: